



DOCKET NO.: B00801.70187.US


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Brenner et al.  
Serial No.: 09/654,328  
Confirmation No.: 5793  
Filed: September 1, 2000  
For: METHODS AND COMPOSITIONS FOR TREATMENT OF  
INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING  
AGENTS  
Examiner: Haddad, Maher M.  
Art Unit: 1644

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP RCE Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 14th day of July, 2003.

  
Edward R. Gates

---

**MAIL STOP RCE**  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

This amendment is filed in response to the Office Action mailed from the Patent Office on January 14, 2003 (Paper No. 14). Applicants respectfully request a three month extension of time and submit the appropriate fee concurrently herewith. Also enclosed is a Request for Continued Examination and the appropriate fee. Applicants are a small entity and hereby assert small entity status.

**Telephone Interview with the Examiner**

Applicants wish to thank Examiners Haddad and Chan for the opportunity to conduct a telephone interview on April 14, 2003. During that interview, the outstanding enablement rejection was discussed and Applicants agreed to submit a declaration to show that the cadherin-11-Fc fusion protein mimics an anti-cadherin antibody and that in vivo administration of cadherin-11-Fc fusion protein does not induce an active immune response.